The expression of the 16 oncogenes and five reference genes measured by the Oncotype DX test is used to calculate a Recurrence Score® result between 0 and 100, which can predict prognosis and whether adjuvant chemotherapy is of benefit for patients with early-stage HR+/HER2- N0 breast cancer [9–11]. This evidence concerns the gene ERBB2 and breast carcinoma.